When does the Evenity (romosozumab) patent expire in Australia?
I don’t have the specific Australian patent expiry dates for Evenity from the information provided. Patent expiry in Australia depends on the exact patents covering romosozumab (including any supplementary protection certificates, if applicable), and the relevant patent numbers.
Which Australian patents control Evenity’s exclusivity?
In Australia, exclusivity can be driven by one or more IP rights, not a single “one date” for the product. To pin down the expiry, you typically need the specific Australian patent(s) listed for Evenity (romosozumab) and check each one’s:
- filing and grant details
- term adjustments or extensions (if any)
- whether any supplementary protection certificate (SPC) exists for the underlying medicine
How do patent expiry and PBS listing timelines interact?
Even if a patent expires, a medicine may remain costly or restricted until any related regulatory and pricing periods end. In practice, the earliest time a competitor can sell a generic or biosimilar in Australia depends on both:
- IP status (patents/SPC or other protections)
- whether the product has an approved pathway and supply arrangements for Australia’s market
What if you need the exact date for investors, competitors, or procurement?
If you share either of the following, I can help you translate it into the likely “expiry in Australia” answer format:
- the Australian patent number(s) covering Evenity (or a link to the IP summary you’re using), or
- the IP summary text you have (for example, from a patent register or legal brief)
Then you can identify the controlling expiry date(s) for the specific claims in Australia.
Sources
No sources were provided with the prompt, so I can’t cite any Australian patent or exclusivity dates for Evenity.